Drugs for Non-small Cell Lung Cancer Market Report

Europe Drugs for Non-small Cell Lung Cancer Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 04, 2020
  • PAGES：189
  • REPORT CODE：GMM537305
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Drugs for Non-small Cell Lung Cancer market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 2.3% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Drugs for Non-small Cell Lung Cancer Market Segmentations:

    By Player:

    • Intas Pharmaceuticals

    • Curis

    • Ziopharm Oncology

    • Cornerstone Pharmaceuticals

    • Exelixis

    • BioMarin Pharmaceutical

    • Hikma Pharmaceuticals

    • CytRx

    • Amgen

    • Hospira

    • Karyopharm Therapeutics

    • Menarini

    • Cerulean Pharma

    • Genentech

    • CellAct Pharma

    • Fresenius Kabi

    • Cipla

    • Kyowa Hakko Kirin

    • Alchemia

    • Apotex

    • Eli Lilly

    • Ligand Pharmaceuticals

    • Bristol-Myers Squibb

    • Sanofi

    • GlaxoSmithKline

    By Type:

    • Radiofrequency Ablation (RFA)

    • Radiation Therapy

    • Chemotherapy

    • Targeted Therapies

    • Immunotherapy

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Drugs for Non-small Cell Lung Cancer Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Radiofrequency Ablation (RFA) from 2014 to 2026

    • 1.3.2 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Radiation Therapy from 2014 to 2026

    • 1.3.3 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Chemotherapy from 2014 to 2026

    • 1.3.4 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Targeted Therapies from 2014 to 2026

    • 1.3.5 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Immunotherapy from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.2 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Clinic from 2014 to 2026

    • 1.4.3 Europe Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Drugs for Non-small Cell Lung Cancer Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Drugs for Non-small Cell Lung Cancer by Major Types

      • 3.4.1 Market Size and Growth Rate of Radiofrequency Ablation (RFA)

      • 3.4.2 Market Size and Growth Rate of Radiation Therapy

      • 3.4.3 Market Size and Growth Rate of Chemotherapy

      • 3.4.4 Market Size and Growth Rate of Targeted Therapies

      • 3.4.5 Market Size and Growth Rate of Immunotherapy

    4 Segmentation of Drugs for Non-small Cell Lung Cancer Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Drugs for Non-small Cell Lung Cancer by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hospital for Construction

      • 4.4.2 Market Size and Growth Rate of Clinic for Construction

      • 4.4.3 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Drugs for Non-small Cell Lung Cancer Production Analysis by Top Regions

    • 5.2 Europe Drugs for Non-small Cell Lung Cancer Consumption Analysis by Top Regions

    • 5.3 Europe Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.3 France Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    6 Product Circulation of Drugs for Non-small Cell Lung Cancer Market among Top Countries

    • 6.1 Top 5 Export Countries in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 7.1 Germany Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 7.2 Germany Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    8. UK Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 8.1 UK Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 8.2 UK Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    9. France Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 9.1 France Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 9.2 France Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    10. Italy Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 10.1 Italy Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 10.2 Italy Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    11. Spain Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 11.1 Spain Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 11.2 Spain Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    12. Poland Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 12.1 Poland Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 12.2 Poland Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    13. Russia Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 13.1 Russia Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 13.2 Russia Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    14. Switzerland Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 14.1 Switzerland Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 14.2 Switzerland Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    15. Turkey Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 15.1 Turkey Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 15.2 Turkey Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Top Countries

      • 16.3.1 Denmark Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 16.3.2 Finland Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 16.3.3 Norway Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 16.3.4 Sweden Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 16.3.6 Iceland Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Top Countries

      • 17.3.1 Belgium Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 17.3.2 Netherlands Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 17.3.3 Luxembourg Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Landscape Analysis by Top Countries

      • 18.3.1 Estonia Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 18.3.2 Latvia Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

      • 18.3.3 Lithuania Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Intas Pharmaceuticals

      • 19.1.1 Intas Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Curis

      • 19.2.1 Curis Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Ziopharm Oncology

      • 19.3.1 Ziopharm Oncology Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Cornerstone Pharmaceuticals

      • 19.4.1 Cornerstone Pharmaceuticals Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Exelixis

      • 19.5.1 Exelixis Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 BioMarin Pharmaceutical

      • 19.6.1 BioMarin Pharmaceutical Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Hikma Pharmaceuticals

      • 19.7.1 Hikma Pharmaceuticals Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 CytRx

      • 19.8.1 CytRx Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Amgen

      • 19.9.1 Amgen Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Hospira

      • 19.10.1 Hospira Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Karyopharm Therapeutics

      • 19.11.1 Karyopharm Therapeutics Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Menarini

      • 19.12.1 Menarini Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Cerulean Pharma

      • 19.13.1 Cerulean Pharma Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Genentech

      • 19.14.1 Genentech Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 CellAct Pharma

      • 19.15.1 CellAct Pharma Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Fresenius Kabi

      • 19.16.1 Fresenius Kabi Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Cipla

      • 19.17.1 Cipla Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Kyowa Hakko Kirin

      • 19.18.1 Kyowa Hakko Kirin Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Alchemia

      • 19.19.1 Alchemia Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Apotex

      • 19.20.1 Apotex Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    • 19.21 Eli Lilly

      • 19.21.1 Eli Lilly Company Profile and Development Status

      • 19.21.2 Market Performance

      • 19.21.3 Product and Service Introduction

    • 19.22 Ligand Pharmaceuticals

      • 19.22.1 Ligand Pharmaceuticals Company Profile and Development Status

      • 19.22.2 Market Performance

      • 19.22.3 Product and Service Introduction

    • 19.23 Bristol-Myers Squibb

      • 19.23.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.23.2 Market Performance

      • 19.23.3 Product and Service Introduction

    • 19.24 Sanofi

      • 19.24.1 Sanofi Company Profile and Development Status

      • 19.24.2 Market Performance

      • 19.24.3 Product and Service Introduction

    • 19.25 GlaxoSmithKline

      • 19.25.1 GlaxoSmithKline Company Profile and Development Status

      • 19.25.2 Market Performance

      • 19.25.3 Product and Service Introduction

    The List of Tables and Figures (Totals 77 Figures and 133 Tables)

    • Figure Product Picture

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Radiofrequency Ablation (RFA) Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Radiation Therapy Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Chemotherapy Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Targeted Therapies Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Immunotherapy Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Clinic from 2014 to 2026

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure UK Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure France Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Drugs for Non-small Cell Lung Cancer Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Drugs for Non-small Cell Lung Cancer

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Drugs for Non-small Cell Lung Cancer by Different Types from 2014 to 2026

    • Table Consumption Share of Drugs for Non-small Cell Lung Cancer by Different Types from 2014 to 2026

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Radiofrequency Ablation (RFA) Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Radiation Therapy Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Chemotherapy Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Targeted Therapies Market, 2015 - 2026 (USD Million)

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Immunotherapy Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Drugs for Non-small Cell Lung Cancer by Different End-Users from 2014 to 2026

    • Table Consumption Share of Drugs for Non-small Cell Lung Cancer by Different End-Users from 2014 to 2026

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Clinic from 2014 to 2026

    • Figure Drugs for Non-small Cell Lung Cancer Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Drugs for Non-small Cell Lung Cancer Production by Major Regions

    • Table Europe Drugs for Non-small Cell Lung Cancer Production Share by Major Regions

    • Figure Europe Drugs for Non-small Cell Lung Cancer Production Share by Major Countries and Regions in 2014

    • Table Europe Drugs for Non-small Cell Lung Cancer Consumption by Major Regions

    • Table Europe Drugs for Non-small Cell Lung Cancer Consumption Share by Major Regions

    • Table Germany Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table UK Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table France Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Italy Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Spain Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Poland Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Russia Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Switzerland Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Turkey Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Drugs for Non-small Cell Lung Cancer Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Germany Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Germany Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Germany Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table UK Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table UK Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table UK Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table UK Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table France Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table France Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table France Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table France Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Italy Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Italy Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Italy Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Italy Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Spain Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Spain Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Spain Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Spain Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Poland Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Poland Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Poland Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Poland Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Russia Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Russia Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Russia Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Russia Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Switzerland Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Switzerland Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Switzerland Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Turkey Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Turkey Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Turkey Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Drugs for Non-small Cell Lung Cancer Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Drugs for Non-small Cell Lung Cancer Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Drugs for Non-small Cell Lung Cancer Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Drugs for Non-small Cell Lung Cancer Market Volume and Growth Rate from 2014 to 2026

    • Table Intas Pharmaceuticals Profiles

    • Table Intas Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Intas Pharmaceuticals Product benchmarking

    • Table Intas Pharmaceuticals Strategic initiatives

    • Table Intas Pharmaceuticals SWOT analysis

    • Table Curis Profiles

    • Table Curis Production, Value, Price, Gross Margin 2014-2019

    • Table Curis Product benchmarking

    • Table Curis Strategic initiatives

    • Table Curis SWOT analysis

    • Table Ziopharm Oncology Profiles

    • Table Ziopharm Oncology Production, Value, Price, Gross Margin 2014-2019

    • Table Ziopharm Oncology Product benchmarking

    • Table Ziopharm Oncology Strategic initiatives

    • Table Ziopharm Oncology SWOT analysis

    • Table Cornerstone Pharmaceuticals Profiles

    • Table Cornerstone Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Cornerstone Pharmaceuticals Product benchmarking

    • Table Cornerstone Pharmaceuticals Strategic initiatives

    • Table Cornerstone Pharmaceuticals SWOT analysis

    • Table Exelixis Profiles

    • Table Exelixis Production, Value, Price, Gross Margin 2014-2019

    • Table Exelixis Product benchmarking

    • Table Exelixis Strategic initiatives

    • Table Exelixis SWOT analysis

    • Table BioMarin Pharmaceutical Profiles

    • Table BioMarin Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table BioMarin Pharmaceutical Product benchmarking

    • Table BioMarin Pharmaceutical Strategic initiatives

    • Table BioMarin Pharmaceutical SWOT analysis

    • Table Hikma Pharmaceuticals Profiles

    • Table Hikma Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Hikma Pharmaceuticals Product benchmarking

    • Table Hikma Pharmaceuticals Strategic initiatives

    • Table Hikma Pharmaceuticals SWOT analysis

    • Table CytRx Profiles

    • Table CytRx Production, Value, Price, Gross Margin 2014-2019

    • Table CytRx Product benchmarking

    • Table CytRx Strategic initiatives

    • Table CytRx SWOT analysis

    • Table Amgen Profiles

    • Table Amgen Production, Value, Price, Gross Margin 2014-2019

    • Table Amgen Product benchmarking

    • Table Amgen Strategic initiatives

    • Table Amgen SWOT analysis

    • Table Hospira Profiles

    • Table Hospira Production, Value, Price, Gross Margin 2014-2019

    • Table Hospira Product benchmarking

    • Table Hospira Strategic initiatives

    • Table Hospira SWOT analysis

    • Table Karyopharm Therapeutics Profiles

    • Table Karyopharm Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Karyopharm Therapeutics Product benchmarking

    • Table Karyopharm Therapeutics Strategic initiatives

    • Table Karyopharm Therapeutics SWOT analysis

    • Table Menarini Profiles

    • Table Menarini Production, Value, Price, Gross Margin 2014-2019

    • Table Menarini Product benchmarking

    • Table Menarini Strategic initiatives

    • Table Menarini SWOT analysis

    • Table Cerulean Pharma Profiles

    • Table Cerulean Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Cerulean Pharma Product benchmarking

    • Table Cerulean Pharma Strategic initiatives

    • Table Cerulean Pharma SWOT analysis

    • Table Genentech Profiles

    • Table Genentech Production, Value, Price, Gross Margin 2014-2019

    • Table Genentech Product benchmarking

    • Table Genentech Strategic initiatives

    • Table Genentech SWOT analysis

    • Table CellAct Pharma Profiles

    • Table CellAct Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table CellAct Pharma Product benchmarking

    • Table CellAct Pharma Strategic initiatives

    • Table CellAct Pharma SWOT analysis

    • Table Fresenius Kabi Profiles

    • Table Fresenius Kabi Production, Value, Price, Gross Margin 2014-2019

    • Table Fresenius Kabi Product benchmarking

    • Table Fresenius Kabi Strategic initiatives

    • Table Fresenius Kabi SWOT analysis

    • Table Cipla Profiles

    • Table Cipla Production, Value, Price, Gross Margin 2014-2019

    • Table Cipla Product benchmarking

    • Table Cipla Strategic initiatives

    • Table Cipla SWOT analysis

    • Table Kyowa Hakko Kirin Profiles

    • Table Kyowa Hakko Kirin Production, Value, Price, Gross Margin 2014-2019

    • Table Kyowa Hakko Kirin Product benchmarking

    • Table Kyowa Hakko Kirin Strategic initiatives

    • Table Kyowa Hakko Kirin SWOT analysis

    • Table Alchemia Profiles

    • Table Alchemia Production, Value, Price, Gross Margin 2014-2019

    • Table Alchemia Product benchmarking

    • Table Alchemia Strategic initiatives

    • Table Alchemia SWOT analysis

    • Table Apotex Profiles

    • Table Apotex Production, Value, Price, Gross Margin 2014-2019

    • Table Apotex Product benchmarking

    • Table Apotex Strategic initiatives

    • Table Apotex SWOT analysis

    • Table Eli Lilly Profiles

    • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

    • Table Eli Lilly Product benchmarking

    • Table Eli Lilly Strategic initiatives

    • Table Eli Lilly SWOT analysis

    • Table Ligand Pharmaceuticals Profiles

    • Table Ligand Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Ligand Pharmaceuticals Product benchmarking

    • Table Ligand Pharmaceuticals Strategic initiatives

    • Table Ligand Pharmaceuticals SWOT analysis

    • Table Bristol-Myers Squibb Profiles

    • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

    • Table Bristol-Myers Squibb Product benchmarking

    • Table Bristol-Myers Squibb Strategic initiatives

    • Table Bristol-Myers Squibb SWOT analysis

    • Table Sanofi Profiles

    • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

    • Table Sanofi Product benchmarking

    • Table Sanofi Strategic initiatives

    • Table Sanofi SWOT analysis

    • Table GlaxoSmithKline Profiles

    • Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019

    • Table GlaxoSmithKline Product benchmarking

    • Table GlaxoSmithKline Strategic initiatives

    • Table GlaxoSmithKline SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US